Pharmacology of Anthelmintics

  • H. Vanden Bossche
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 77)


As noted in the different chapters of this volume, most infections due to worms living in the gastrointestinal tract can now be cured by anthelmintics. In general these drugs can be divided into four classes: herbal preparations, inorganic and metallorganic compounds, “antibiotics,” and synthetic organic compounds.


Schistosomiasis Schistosoma Carbendazim Adipate Naphthoate 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Actor P, Anderson EL, Dicuollo CJ, Ferlanto RJ, Hoover JRE, Pagano JF, Ravin LR, Scheidy SF, Stedman RJ, Theodorides VJ (1967) New broad spectrum anthelmintic, methyl 5(6)-butyl-2-benzimidazolecarbamate. Nature 215:321–322PubMedCrossRefGoogle Scholar
  2. Aldridge WN, Holmstedt B (1981) History and scope of the conference. Acta Pharmacol Toxicol [Suppl V] 49:3–6CrossRefGoogle Scholar
  3. Andrews P (1981) A summary of the efficacy of praziquantel against schistosomes in animal experiments and notes on its mode of action. Arzneimittelforsch 31:538–541PubMedGoogle Scholar
  4. Andrews P, Thomas H (1983) Praziquantel. Medical Research Reviews 3:147–200CrossRefGoogle Scholar
  5. Andrews P, Dycka J, Frank G (1980) Effect of praziquantel on clinical-chemical parameters in healthy and schistosome-infected mice. Ann Trop Med Parasitol 74:167–177PubMedGoogle Scholar
  6. Aronson CE, Serlick ER (1977) Effects of disophenol on the isolated perfused rat heart. Biochem Pharmacol 26:2297–2305PubMedCrossRefGoogle Scholar
  7. Aubry ML, Cowell P, Davey MJ, Shevde S (1970) Aspects of the pharmacology of a new anthelmintic: pyrantel. Br J Pharmacol 38:332–344PubMedGoogle Scholar
  8. Austin WC, Courtney W, Danilewicz JC, Margan DH, Conover LH, Howes HL, Lynch JE, McFarland JW, Cornwell RL, Theodorides VJ (1966) Pyrantel tartrate, a new anthelmintic effective against infections of domestic animals. Nature 212:1273–1274PubMedCrossRefGoogle Scholar
  9. Averkin EA, Beard CC, Dvorak CA, Edwards JA, Fried JH, Kilan JG, Schiltz RA, Kistner TP, Drudge JH, Lyons ET, Sharp NL, Corwin RM (1975) Methyl 5(6)-phenylsulfinyl- 2-benzimidazole carbamate. A new potent anthelmintic. J Med Chem 11:1164—1166Google Scholar
  10. Barett J (1981) Biochemistry of parasitic helminths. Macmillan, LondonGoogle Scholar
  11. Behm CA, Bryant C (1979) Anthelmintic action. A metabolic approach. Vet Parasitol 5:39–49CrossRefGoogle Scholar
  12. Bellander BTD, Hagmar LE, Osterdahl BG (1981) Nitrosation of piperazine in the stomach. Lancet 2:372PubMedCrossRefGoogle Scholar
  13. Borgers M, Nollin S de (1975) Ultrastruetural changes in Ascaris suum intestine after mebendazole treatment in vivo. J Parasitol 61:110–122PubMedCrossRefGoogle Scholar
  14. Borgers M, Thone F (1976) Further characterization of phosphatase activities using nonspecific substrates. Histochem J 8:301–317PubMedCrossRefGoogle Scholar
  15. Borgers M, Nollin S de, Verheyen A, Brabander M de, Thienpont D (1975 a) Effects of new anthelmintics on the microtubular system of parasites. In: Borgers M, Brabander M de (eds) Microtubules and microtubule inhibitors. Elsevier, Amsterdam, pp 497–508Google Scholar
  16. Borgers M, Nollin S de, Verheyen A, Vanparys O, Thienpont D (1975 b) Morphological changes in cysticerci of Taenia taeniaeformis after mebendazole treatment. J Parasitol 61:830–843PubMedCrossRefGoogle Scholar
  17. Borgers M, Nollins S de, Brabander M de, Thienpont D (1975 c) Influence of the anthelmintic mebendazole on microtubules and intracellular organelle movement in nematode intestinal cells. Am J Vet Res 36:1153–1166PubMedGoogle Scholar
  18. Botero DR (1978) Chemotherapy of human intestinal parasitic diseases. Ann Rev Pharmacol Toxicol 18:1–15CrossRefGoogle Scholar
  19. Boyd JE, Bullock NW, Champagne DA, Gotterdam PE, Morici IJ, Plaisted PH, Spicer LD, Wayne RS, Zulalian J (1969) Metabolism of L-tetramisole in rats. In: 158th National meeting of the American Chemical Society, New York, 7–12 SeptemberGoogle Scholar
  20. Brodie RR, Mayo BC, Chasseaud LF, Hawkings DR (1977) The disposition of radioactivity after administration of the anthelmintic methyl- 14C-5-cyclopropylcarbonyl-2-benz- imidazole carbamate (ciclobendazole) to rats and dogs. Arzneimittelforsch 27:593–598PubMedGoogle Scholar
  21. Broome AWJ (1962) Mechanisms of anthelmintic action with particular reference to drugs affecting neuromuscular activity. In: Goodwin LG, Nimmo-Smith RM (eds) Drugs, parasites and hosts. Churchill, London, pp 43–61Google Scholar
  22. Bryant C, Cornish RA, Rahman MS (1976) Adenine nucleotides as indicators of anthelmintic efficacy. In: Bossche H vanden (ed) Biochemistry of parasites and host- parasite relationships, Elsevier, Amsterdam, pp 599–604Google Scholar
  23. Bryceson ADM, Woestenborghs R, Michiels M, Bossche H vanden (1982) Bioavailability and tolerability of mebendazole in patients with inoperable hydatid disease. Trans R Soc Trop Med Hyg 16:563–564CrossRefGoogle Scholar
  24. Buchanan RA, Barrow WB, Heffelfinger JC, Kinkel AW, Smith TC, Turner JC (1974) Pyr- vinium pamoate. Clin Pharmacol Ther 16:716–719PubMedGoogle Scholar
  25. Bueding E (1969) Some biochemical effects of anthelmintic drugs. Biochem Pharmacol 18:1541–1547PubMedCrossRefGoogle Scholar
  26. Bueding E, Liu CL, Rogers SH (1972) Inhibition by metrifonate and dichlorvos of cho- linesterases in schistosomes. Br J Pharmacol 46:480–487PubMedGoogle Scholar
  27. Bueding E, Batzinger R, Petterson G (1976) Antischistosomal and some toxicological properties of a nitrodiphenylaminoisothiocyanate (C 9330-G0/CGP 4540). Experi- entia 32:604–606Google Scholar
  28. Bühring KU, Diekmann HW, Müller H, Garbe A, Nowak H (1978) Metabolism of praziquantel in man. Eur J Drug Metab Pharmacokinet 3:179–190CrossRefGoogle Scholar
  29. Burg RW, Miller BM, Baker EE, Birnbaum J, Currie SA, Hartman R, Kong YL, Mo- naghan RL, Olson G, Putter I, Tunac JB, Wallick H, Stapley EO, Oiwa R, Omura S (1979) Avermectins, new family of potent anthelmintic agents: producing organism and fermentation. Antimicrob Agents Chemother 15:361–367PubMedGoogle Scholar
  30. Campbell A J, Montague PE (1981) A comparison of the activity of uncouplers of oxidative phosphorylation against the common liver fluke Fasciola hepatica. Mol Biochem Parasitol 4:139–147PubMedCrossRefGoogle Scholar
  31. Campbell WC (1981) An introduction to the avermectins. NZ Vet J 29:174–178CrossRefGoogle Scholar
  32. Castaner J (1978) Febantel - veterinary anthelmintic. Drugs of the future 3:377–378Google Scholar
  33. Cavier R (1973) Chemotherapy of intestinal nematodes. In: Cavier R, Hawking F (eds) Chemotherapy of helminthiasis, vol 1. Pergamon, Oxford, pp 215–436Google Scholar
  34. Cavier R. Hawking F (eds) (1973) Chemotherapy of helminthiasis. Pergamon, OxfordGoogle Scholar
  35. Christ O, Kellner H-M, Klöpffer G (1974) Studies on pharmacokinetics and metabolism with fenbendazole - a new anthelmintic. In: Proceedings 3rd international congress of parasitology, vol 3. Facta Publication, Vienna, pp 1448–1449Google Scholar
  36. Chubb JM, Bennett JL, Akera T, Brody TM (1978) Effects of praziquantel, a new anthelmintic, on electromechanical properties of isolated rat atria. J Pharmacol Exp Ther 207:284–293PubMedGoogle Scholar
  37. Coles GC (1977) The biochemical mode of action of some modern anthelmintics. Pestic Sci 8:536—543CrossRefGoogle Scholar
  38. Coles GC (1979) The effect of praziquantel on Schistosoma manson. J Helminthol 53:31–33PubMedCrossRefGoogle Scholar
  39. Coles GC, East JM, Jenkins SN (1975) The mechanism of action of the anthelmintic leva- misole. Gen Pharmacol 6:309–313CrossRefGoogle Scholar
  40. Comley JCW (1980) Ultrastructure of the intestinal cells ofAspiculuris tetraptera after in vivo treatment of mice with mebendazole and thiabendazole. Int J Parasitol 10:143–150PubMedCrossRefGoogle Scholar
  41. Cornish RA, Bryant C (1976) Changes in energy metabolism due to anthelmintics in Fasciola hepatica maintained in vitro. Int J Parasitol 6:393–398PubMedCrossRefGoogle Scholar
  42. Cornish RA, Behm CA, Butler RW, Bryant C (1977) The in vivo effects of rafoxanide on the energy metabolism of Fasciola hepatica. Int J Parasitol 7:217–220PubMedCrossRefGoogle Scholar
  43. Cornwell RL (1966) Controlled laboratory trials in sheep with the anthelmintic pyrantel startrate. Vet Ree 79:590–595CrossRefGoogle Scholar
  44. Cross BG, David A, Vallance DK (1954) Piperazine adipate: a new anthelmintic agent. J Pharm Pharmacol 6:711–717CrossRefGoogle Scholar
  45. Davidse LC (1976) The antimitotic properties of the benzimidazole fungicide carbendazim and a mechanism of resistance to this compound in Aspergillus nidulans. Thesis, Land- bouwhogeschool, Binnenhaven 9, WageningenGoogle Scholar
  46. Davidse LC, Flach W (1978) Interaction of thiabendazole with fungal tubulin. Biochim BiophysActa 543:82–90Google Scholar
  47. Davis A (1973) Drug treatment in intestinal helminthiases. World Health Organization, GenevaGoogle Scholar
  48. Davis A (1975) Clinical available antischistosomal drugs. J Toxicol Environ Health 1:191- 201Google Scholar
  49. Davis A, Biles JE, Ulrich AM, Dixon H (1981) Tolerance and efficacy of praziquantel in phase IIA and II B therapeutic trials in Zambian patients. Arzneimittelforsch 31:568- 574Google Scholar
  50. Degremont A, Stahel E (1978) Klinische Bewertung von Ciclobendazol (C-C 2481) bei der Behandlung von Wurmkrankungen des Darmes. Schweiz Med Wochenschr 108:1430— 1433Google Scholar
  51. Delatour P, Burgat-Sacaze V (1981) Vers une procedure alternative d’évaluation toxicolo- gique des résidus? Application aux anthelminthiques dérivés du benzimidazole. Reel Med Vet 157:213–218Google Scholar
  52. Delatour P, Lorgue G, Lapras M, Deschanel J-P (1974) Propriétés embryotoxiques (rat) et résidus (ovins, bovins) de trois anthelmintiques dérivés du benzimidazole. Bull Soc Sci Vét Méd Comp 76:147–154Google Scholar
  53. Delatour P, Lorgue G, Lapras M, Richard Y (1976 a) Propriétés embryotoxiques et antimitotiques du parbendazole, mebendazole et du cambendazole. CR Séances Acad Sci 282:517–518Google Scholar
  54. Delatour P, Lorgue G, Courtot D, Lapras M (1976 b) Tolerance embryonaire de Foxiben- dazole chez le rat et le mouton. Reel Med Vet 152:467–470Google Scholar
  55. Delatour P, Debroye J, Lorgue G, Courtot D (1977) Embryotoxicité experimentale de l’ox- fendazole chez le rat et le mouton. Reel Med Vet 153:639–645Google Scholar
  56. Del Castillo J (1969) Pharmacology of nematoda. In: Florkin M, Scheer BT (eds) ChemicalGoogle Scholar
  57. zoology, vol 3. Academic, New York, pp 521–554Google Scholar
  58. Demoen P, Aelst C van, Loomans J, Verhaegen H, Cree J de, Verbruggen F, Ringoir S (1973) The absorption and urinary excretion of mebendazole after oral administration. In: Clin Res Report, R 17 635/36 Janssen Pharmaceutica, BeerseGoogle Scholar
  59. De Nollin S, Bossche H vanden (1973) Biochemical effects of mebendazole on Trichinella spiralis larvae. J Parasitol 59:970–976PubMedCrossRefGoogle Scholar
  60. Dicuollo CJ, Miller JA, Coiman WF, Kraeer PM, Wong MY (1977) Albendazole metabolic and tissue residue studies in sheep and cattle. In: Proceeding of the 8th international conference of WAAVP, Sydney Juli (Abstract)Google Scholar
  61. Diekmann HW, Bühring KU (1976) The fate of praziquantel in the organism III. Metabolism in rat, beagle dog and rhesus monkey. Eur J Drug Metab Pharmacokinet 2:107- 112CrossRefGoogle Scholar
  62. Druckrey M, Preussman R, Ivankovic S, Schmähl D (1967) Organotrope carcinogene Wirkungen bei 65 verschiedenen TV-Nitroso-Verbindungen an BD-Ratten. Z Krebsforsch 69:103–201PubMedCrossRefGoogle Scholar
  63. Drugs of Today vol 17 (1981) Oxantel pamoate/pyrantel pamoate. In: Leeson PA, Mealy NE (eds) JR Prous, SA, Barcelona, pp 41–12Google Scholar
  64. Düwel D (1977) Fenbendazole. Biological properties and activity. Pest Sei 8:550–555CrossRefGoogle Scholar
  65. Düwel D (1979) Summary and evaluation of the worldwide published investigations. Hoechst, FrankfurtGoogle Scholar
  66. Düwel D, Schleich H (1978) In vivo investigations on the mode of action of fenbendazole. Zentralbl Veterinaermed [B] 25:800–805CrossRefGoogle Scholar
  67. Düwel D, Hajdu P, Damm D (1975) Zur Pharmakokinetic von Fenbendazol. Berl Munch Tierärztl Wochenschr 88:131–134PubMedGoogle Scholar
  68. Düwel D, Aguilar FJ, Batte EG, Bürger HJ, Thomas RJ, Zahner H (1981) Therapy in nematode and acanthocephalan infections. In: Slusarski W (ed) Review of advances in parasitology. PWN, Warszawa, pp 507–524Google Scholar
  69. Dunn GL, Gallagher G, Davis LD, Hoover JRE, Stedman RJ (1973) Metabolites of methyl 5(6)-butyl-2-benzimidazole carbamate (parbendazole) structure and synthesis. J Med Chem 16:996–1002PubMedCrossRefGoogle Scholar
  70. Egerton JR, Campbell WC (1970) The efficacy of 5-isopropoxy-carbonylamino-2-(4-thiazolyl) benzimidazole against helminths of sheep. Res Vet Sei 11:193–195Google Scholar
  71. Egerton JR, Ostlind DA, Blair LS, Eary CH, Suhoyda D, Cifelli S, Riek RF, Campbell WC (1979) Avermectins, new family of potent anthelmintic agents: efficacy of the Bla component. Antimicrob Agents Chemother 15:372–378PubMedGoogle Scholar
  72. Eichler DA (1973) The anthelmintic activity of thiophanate in sheep and cattle. Br Vet J 129:533–543PubMedGoogle Scholar
  73. Eichler DA (1974) The toxicity of thiophanate (“Nemafax”) in sheep and cattle. Br Vet J 130:570–576PubMedGoogle Scholar
  74. Eyre P (1970) Some pharmacodynamic effects of the nematodes: methyridine, tetramisole and pyrantel. J Pharm Pharmacol 22:26–36PubMedCrossRefGoogle Scholar
  75. Fetterer RH, Pax RA, Thompson D, Bricker C, Bennett JL (1980 a) Praziquantel: mode of its antischistosomal action. In: Bossche H vanden (ed) The host invader interplay. Elsevier, Amsterdam, pp 695–698Google Scholar
  76. Fetterer RH, Pax RA, Bennett JL (1980 b) Praziquantel, potassium and 2,4-dinitrophenol: analysis of their action on the musculature of Schistosoma mansoni. Eur J Pharmacol 64:31–38PubMedCrossRefGoogle Scholar
  77. Friedman PA, Platzer EG (1978) Interaction of anthelmintic benzimidazoles and benzimidazole derivatives with bovine brain tubulin. Biochim Biophys Acta 544:605–614PubMedCrossRefGoogle Scholar
  78. Friedman PA, Platzer EG (1980 a) The molecular mechanism of action of benzimidazoles in embryos of Ascaris suum. In: Bossche H vanden (ed) The host invader interplay. Elsevier, Amsterdam, pp 595–604Google Scholar
  79. Friedman PA, Platzer EG (1980 b) Interaction of anthelmintic benzimidazoles with Ascaris suum embryonic tubulin. Biochim Biophys Acta 630:271–278PubMedCrossRefGoogle Scholar
  80. Fritz LC, Wang CC, Gorio A (1979) Avermectin Bla irreversibly blocks postsynaptic potentials at the bolster neuromuscular junction by reducing muscle membrane resistance. Proc Natl Acad Sei USA 76:2062–2066CrossRefGoogle Scholar
  81. Frohberg H, Schencking MS (1981) Toxicological profile of praziquantel, a new drug against cestode and schistosome infections, as compared to some other schistosomicides. Arzneimittelforsch 31:555–565PubMedGoogle Scholar
  82. Garcia EG (1976) Treatment for trichuriasis with oxantel. Am J Trop Med Hyg 25:914–915PubMedGoogle Scholar
  83. Garcia H, Keefer L, Lyinsky W, Wenyon CEM (1970) Carcinogenicity of nitrosothiomor- pholine and 1 nitrosopiperazine in rats. Z Krebsforsch 74:179–184PubMedCrossRefGoogle Scholar
  84. Garin JP, Kalb JC, Despeignes J, Vincent G (1970) Action des antibiotiques oligosaccharides sur Taenia saginata. J Parasitol 56:112 (No 4, section II, part 1)Google Scholar
  85. Gönnert R, Andrews P (1977) Praziquantel, a new broad-spectrum antischistostomal agent. Z Parasitenkd 52:129–150PubMedCrossRefGoogle Scholar
  86. Gönnert R, Johannis J, Schraufstätter E, Strufe R (1963) Konstitution und Cestocide Wirkung in der Yomesan-Reiche. In: Medizin und Chemie. Bayer, Leverkusen, pp 540–567Google Scholar
  87. Goodwin LG (1980) New drugs for old diseases. Trans R Soc Trop Med Hyg 74:1–7PubMedCrossRefGoogle Scholar
  88. Graziani G, Martin GL de (1977 a) Pharmacokinetic studies on levamisole. Drugs Exp Clin Res 2:221–223Google Scholar
  89. Graziani G, Martin GL de (1977 b) Pharmacokinetic studies on levamisole: on the pharmacokinetics and relative bioavailability of levamisole in man. Drugs Exp Clin Res 2:235- 240Google Scholar
  90. Hall CA, Kelly JD, Campbell NJ, Whitlock HV, Martin ICA (1978) The dose response of several benzimidazole anthelmintics against resistant strains of Haemonchus contortus andTrichostrongylus colubriformis selected with thiabendazole. Res Vet Sei 25:364–367Google Scholar
  91. Hamajima F (1973) Studies on metabolism of lung fluke genus Paragonimus. VII. Action of bithionol on glycolytic and oxidative metabolism of adult worms. Exp Parasitol 34:1–11PubMedCrossRefGoogle Scholar
  92. Hashimoto Y, Makita T, Ohnuma N, Noguchi T (1972) Acute toxicity on dimethyl 4,4’-0 phenylene bis (3-thioallophanate), thiophanate-methyl fungicide. Toxicol Appl Pharmacol 23:606–615PubMedCrossRefGoogle Scholar
  93. Hecht G, Gloxhuber Chr (1960) Experimentelle Untersuchungen mit N-(2’-Chlor-4’-Nitro- phenyl)-5-Chlorsalicylamid, einem neuen Bandwurmmittel: toxicologische Untersuchungen. Arzneimittelforsch 10:884–885PubMedGoogle Scholar
  94. Hefferren JJ, Schrotenboer G, Wolman W (1955) Preparation and properties of citric acid and tartaric acid and salts of piperazine. J Am Pharmacol Assoc 44:678–682CrossRefGoogle Scholar
  95. Heykants J (1972) The excretion and metabolism of mebendazole (R 17 635) in the dog. In: Biol Res Report, serial no R 17 635/3. Janssen Pharmaceutica, BeerseGoogle Scholar
  96. Hoebeke J, Neyen G van, Brabander M de (1976) Interaction of oncodazole (R17 934) a new anti-tumoral drug, with rat brain tubulin. Biochem Biophys Res Commun 69:319- 324Google Scholar
  97. Hoff DR, Fisher MH, Bochis RJ, Lusi A, Waksmunski F, Egerton JR, Yakstis JJ, Cuckler AC, Campbell WC (1970) A new broad-spectrum anthelmintic: 2-(4-thiazolyl)-5 iso- propoxycarbonylamino-benzimidazole. Experientia 26:550–551PubMedCrossRefGoogle Scholar
  98. Hogg RA (1978) Death after cambendazole dosing. Vet Ree (Nov 18):477–478CrossRefGoogle Scholar
  99. Ireland M, Gull K, Gutteridge WE, Pogson CI (1979) The interaction of benzimidazole carbamates with mammalian microtubule protein. Biochem Pharmacol 28:2680–2682PubMedCrossRefGoogle Scholar
  100. Janssen PAJ (1976) The levamisole story. In: Jucker E (ed) Progress research, vol 20. Birkhäuser, Basel, pp 347–383Google Scholar
  101. Janssen Pharmaceutica (1972) Mebendazole synopsis. BeerseGoogle Scholar
  102. Johns DJ, Philip JR (1977) Albendazole: safety in sheep. Abstr Pap 8th Int Conf For Adv of Vet Par, SydneyGoogle Scholar
  103. Junod Ch (1965) Essai de traitement de la trichocephalose par la diphetarsone. Bull Soc Pathol Exot Filiales 58:653–660PubMedGoogle Scholar
  104. Kaiser JA (1964) Studies on the toxicity of disophenol (2,6-diiodo-4-nitrophenol) to dogs and rodents plus some comparisons with 2,4-dinitrophenol. Toxicol Appl Pharmacol 6:232–244CrossRefGoogle Scholar
  105. Kane HJ, Behm CA, Bryant C (1980) Metabolic studies on the new fasciolicidal drug, closantel. Mol Biochem Parasitol 1:347–355CrossRefGoogle Scholar
  106. Kass IS, Wang CC, Walrond JP, Stretton AOW (1980) Avermectin Bla, a paralyzing anthelmintic that affects interneurons and inhibitory motoneurons in Ascaris. Proc Natl Acad Sei USA 77:6211–6215CrossRefGoogle Scholar
  107. Kaushik RK, Katiyar JC, Sen AB (1974) Studies on the mode of action of anthelmintics with Ascaridia galli as the test parasite. Indian J Med Res 62:1367–1375PubMedGoogle Scholar
  108. Köhler P, Bachmann R (1980) The possible mode of action of mebendazole in Ascaris suum. In: Bossche H vanden (ed) The host invader interplay. Elsevier, Amsterdam, pp 727–730Google Scholar
  109. Köhler P, Bachmann R (1981) Intestinal tubulin as possible target for the chemotherapeutic action of mebendazole in parasitic nematodes. Mol Biochem Parasitol 4:325–336PubMedCrossRefGoogle Scholar
  110. Lapras M, Deshanel JP, Delatour R, Gastellu J, Lombard M (1973) Accidents tératologi- ques chez le mouton après administration de parbendazole. Bull Soc Sci Vét Méd Comp 75:53–61Google Scholar
  111. Machemer L (1981) Chronic toxicity of metrifonate. Acta Pharmacol Toxicol [Suppl V] 43:15–28Google Scholar
  112. Malkin MF, Camacho RM (1977) The effect of thiabendazole on fumarate reductase from thiabendazole-sensitive and resistant Haemonchus conturtus. J Parasitol 58:845–846CrossRefGoogle Scholar
  113. Marriner SE, Bogan J A (1980) Pharmacokinetics of albendazole in sheep. Am J Vet Res 41:1126–1129PubMedGoogle Scholar
  114. Marriner SE, Bogan JA (1981) Pharmacokinetics of oxfendazole in sheep. Am J Vet Res 42:1143–1145PubMedGoogle Scholar
  115. Marsboom R (1973) Toxicological studies on mebendazole. Toxicol Appl Pharmacol 24:371–377PubMedCrossRefGoogle Scholar
  116. McCracken RO, Stillwell WH, Hudson HM (1982) A possible biochemical mode of action of benzimidazole anthelmintics. Mol Biochem Parasitol [Suppl] 726Google Scholar
  117. Mehlhorn H, Becker B, Andrews P, Thomas H, Frenkel JK (1981) In vivo and in vitro experiments on the effects of praziquantel on Schistosoma mansoni. A light and electron microscopic study. Arzneimittelforsch 31:544–554PubMedGoogle Scholar
  118. Mehlhorn H, Kojima S, Rim HJ, Ruenwongsa P, Andrews P, Thomas H, Bunnag B (1983) Ultrastructural investigations on the effects of praziquantel on human trematodes from Asia: Clonorchis sinensis, Metagonimus Yokogawai, Opisthorchis viverrini, Paragonimus westermani andSchistosoma japonicum. Arzneimittelforsch 33:91–98PubMedGoogle Scholar
  119. Merck (1981) Ivermectin, annotated bibliography, June. DarmstadtGoogle Scholar
  120. Metcalf RL, Fukuto RB, March RB (1959) Toxic action of Dipterex® and DDVP to the house fly. J Econ Entomol 52:44–49Google Scholar
  121. Metzger H, Duwel D (1974) The development of anthelmintics, based on investigation of metabolism of the liver fluke (Fasciola hepatica). Proceedings of the third international congress of parasitology, vol 3, pp 1444–1449. Abstract No. E8(4). Facta publication, ViennaGoogle Scholar
  122. Meuldermans WEG, Hurkmans RM A, Lauwers WFJ, Heykants JJP (1976) The in vitro metabolism of mebendazole in pig, rat, and dog liver fractions. Eur J Drug Metab Pharmacokinet 1:35–40CrossRefGoogle Scholar
  123. Meuldermans W, Hurkmans R, Swijsen E, Heykants J (1977) A comparative study on the excretion and metabolism of flubendazole (R 17 889) and mebendazole (R 17 635) in the rat. In: Preclin Res Report, R17 889/5. Janssen Pharmaceutica BeerseGoogle Scholar
  124. Michiels M, Woestenborghs R, Heykants J (1977 a) On the absorption and distribution of closantel (R 31 520) in sheep after oral and intramuscular administration. Janssen Research Products Information Service, BeerseGoogle Scholar
  125. Michiels M, Heykants J, Sneyers R, Wynants J, Marsboom R (1977 b) Residual tissue levels of flubendazole in the pig after a single oral administration. In: Preclin Res Report, R 17 889/6. Janssen Pharmaceutica BeerseGoogle Scholar
  126. Michiels M, Woestenborghs R, Heykants J (1978) Plasma concentrations of closantel in cattle after a single intramuscular or subcutaneous administration. Janssen Research Products Information Service, BeerseGoogle Scholar
  127. Michiels M, Hendriks R, Heykants J, Bossche H vanden (1982) The pharmacokinetics of mebendazole and flubendazole in animals and man. Arch Int Pharmacodyn Ther 256:180–191PubMedGoogle Scholar
  128. Mirvish SS (1975) Formation of N-nitroso compounds: chemistry, kinetics, and in vivo occurrence. Toxicol Appl Pharmacol 31:325—351PubMedCrossRefGoogle Scholar
  129. Miko M, Chance B (1975) Isothiocyanates, a new class of uncouplers. Biochim Biophys Acta 396:165–174PubMedCrossRefGoogle Scholar
  130. Moreno MS, Barrett J (1979) Monoamine oxidase in adult Hymenolepis diminuta (Cesto-da). Parasitology 78:1–5Google Scholar
  131. Mrozik H, Jones H, Friedman J, Schwartzkopf G, Schardt RA, Patchett AA, Hoff DR, Yakstis JJ, Riek RF, Ostlind DA, Plishker GA, Butler RW, Cuckler AC, Campbell WC (1969) A new agent for the treatment of liver fluke infection (fascioliasis). Experientia 25:883PubMedCrossRefGoogle Scholar
  132. Miinst GJ, Kalaganis G, Bircher J (1980) Plasma concentrations of mebendazole during treatment of echinococcosis. Preliminary results. Eur J Clin Pharmacol 17:375–378CrossRefGoogle Scholar
  133. Niemegeers CJE (1976) Acute intramuscular and oral toxicity of R 31 520 in mice and rats. Janssen Research Products Information ServiceGoogle Scholar
  134. Nordgren I, Bengtsson E, Holmstedt B, Pettersson B-M (1981) Levels of metrifonate and dichlorvos in plasma and erythrocytes during treatment of schistosomiasis with Bilar- cil®. Acta Pharmacol Toxicol [Suppl V] 49:79–86CrossRefGoogle Scholar
  135. Norton S, Beer EJ de (1957) Investigations on the action of piperazine on Ascaris lumbricoides. Am J Trop Med Hyg 6:898–905PubMedGoogle Scholar
  136. O’Brien JJ (1970) Toxicological aspects of some modern anthelmintics. Aust Vet J 46:297- 300PubMedCrossRefGoogle Scholar
  137. Oelkers H-A (1959) Die Chemotherapie der Wurmkrankheiten. In: Jucker E (ed) Progress in drug research, vol 1. Birkhâuser, Basel, pp 159–242Google Scholar
  138. Osteux R, Guerrin F, Lesieur-Demarquilly I (1971) Mode d’action de la pipérazine sur Ascaris lumbricoides var. suum. II. Etude des contractions musculaires deY Ascaris en présence de pipérazine, de coenzyme A et de l’adénosine-triphosphate. Ann Pharm Fr 29:173–178PubMedGoogle Scholar
  139. Pax RA, Bennett JL, Fetterer RH (1978) A benzodiazepine derivative and praziquantel: effects on musculature of Schistosoma mansoni and Schistosoma japonicum. Naunyn Schmiedebergs Arch Pharmacol 304:309–315PubMedCrossRefGoogle Scholar
  140. Phillips JL, Sturman G, West GB (1976) The interaction between anthelmintic drugs and histamine in Ascaris suum. Br J Pharmacol 57:417–420PubMedGoogle Scholar
  141. Pong S-S, Wang CC (1979) Specific binding of avermectin Bla to brain synaptosomes. In:Abstract 11th international congress of biochemistry, Toronto, July.Google Scholar
  142. Pong S-S, Wang CC (1980) The specificity of high-affinity binding of avermectin Bla to mammalian brain. Neuropharmacology 19:311–317PubMedCrossRefGoogle Scholar
  143. Pong S-S, Wang CC, Fritz LC (1980) Studies on the mechanism of action of avermectin Bla: stimulation of release of y-aminobutyric acid from brain synaptosomes. J Neuro- chem 34:351–358Google Scholar
  144. Pouplard L (1976) Les anthelmintiques en médicine vétérinaire 9. Les Nématodes. Ann MédVét 120:515–529Google Scholar
  145. Prichard RK (1970) Mode of action of the anthelmintic thiabendazole in Haemonchus con- tortus. Nature 228:684–685PubMedCrossRefGoogle Scholar
  146. Prichard RK (1973) The fumarate reductase reaction of Haemonchus contortus and the mode of action of some anthelmintics. Int J Parasitol 3:409–417PubMedCrossRefGoogle Scholar
  147. Prichard RK (1974) Exploitation of the comparative biochemistry of the host/parasite system with thiabendazole and related anthelmintics. In: Proceedings 3rd international congress of parasitology, vol 3. Facta Publications, Vienna, pp 1446–1447Google Scholar
  148. Prichard RK (1978) The metabolic profile of adult Fasciola hepatica obtained from rafox-anide-treated sheep. Parasitology 76:277–288PubMedCrossRefGoogle Scholar
  149. Prichard RK, Hennessy DR (1981) Effect of oesophogeal groove closure on the pharmacokinetic behaviour and efficacy of oxfendazole in sheep. Res Vet Sci 30:22–27PubMedGoogle Scholar
  150. Prichard RK, Hennessy DR, Steel JW (1978 a) Prolonged administration: a new concept of increasing the spectrum and effectiveness of anthelmintics. Vet Parasitol 4:309–315Google Scholar
  151. Prichard RK, Kelly JD, Thompson HG (1978 b) The effects of benzimidazole resistance and route of administration on the uptake of fenbendazole and thiabendazole by Haemonchus contortus and Trichostrongylus colubriformis in sheep. Vet Parasitol 4:243–255CrossRefGoogle Scholar
  152. Prichard RK, Kelly JD, Bolin TD, Duncombe VM, Fagan MR (1981 a) The effect of iron and protein deficiency on plasma levels and parasite uptake of [14C]fenbendazole in rats infected with Nippostrongylus brasiliensis. AJEBAK 59:567–573PubMedGoogle Scholar
  153. Prichard RK, Steel JW, Hennessy DR (1981 b) Fenbendazole and thiabendazole in cattle: partition of gastrointestinal absorption and pharmacokinetic behaviour. J Vet Pharmacol Ther 4:295–304PubMedCrossRefGoogle Scholar
  154. Prous JR, Mealy NE, Serradell MN, Blancafort P (1982) Annual drug data report, vol 4. Prous JR, SA, Barcelona, p 30Google Scholar
  155. Raeymaekers AHM, Roevens LFC, Janssen PAJ (1967) The absolute configuration of the optical isomers of the broad spectrum anthelmintic tetramisole. Tetrahedron Lett 1467–1470Google Scholar
  156. Rahman MS, Bryant C (1977) Studies of regulatory metabolism in Moniezia expansa: effects of cambendazole and mebendazole. Int J Parasitol 7:403–409CrossRefGoogle Scholar
  157. Rahman MS, Cornish RA, Chevis RF, Bryant C (1977) Studies of the metabolic changes in parasitic helminths from sheep treated with mebendazole. NZ Vet J 25:79–83CrossRefGoogle Scholar
  158. Reiner E (1981) Esterases on schistosomes: reaction with substrates and inhibitors. Acta Pharmacol Toxicol [Suppl V] 49:72–78CrossRefGoogle Scholar
  159. Rew RS, Smith C, Conglazier ML (1982) Glucose metabolism of Haemonchus contortus adults: effects of thiabendazole on susceptible versus resistant strains. J Parasitol 68:845–850PubMedCrossRefGoogle Scholar
  160. Robinson HJ, Stoerk HC, Graessle OE (1965) Studies on the toxicologic and pharmacologic properties of thiabendazole. Toxicol Appl Pharmacol 7:53–63PubMedCrossRefGoogle Scholar
  161. Rogers EW (1958) Excretion of bephenium salts in urine of human volunteers. Br Med J (2): 1576–1577PubMedCrossRefGoogle Scholar
  162. Romanowski RD, Rhoads ML, Colglazier ML, Kates KC (1975) Effect of cambendazole, thiabendazole and levamisole on fumarate reductase in cambendazole-resistant and -sensitive strains ofHaemonchus contortus. J Parasitol 61:777—778PubMedCrossRefGoogle Scholar
  163. Roseby FB, Boray JC (1970) The anthelmintic efficiency against Fasciola hepatica and the toxicity of BAY 4059 in sheep. Aust Vet J 46:308–310PubMedCrossRefGoogle Scholar
  164. Rousseau F, Haguenoer J-M, Lesieur D, Gamot AP (1981) Gas-chromatographic determination of levamisole in human plasma. Normalization and reliability of the method. Eur J Drug Metab Pharmacokinet 6:281–288PubMedCrossRefGoogle Scholar
  165. Sander J, Labar J, Ladenstein M, Schweinsberg F (1975) Quantitative measurement of in vivo nitrosamine formation. I ARC Sci Publ 9:123–131Google Scholar
  166. Sano M, Terada M, Ishii AI, Kino H (1981) Effects of avermectin Bla on the motility of various parasitic helminths. Experientia 37:844–846PubMedCrossRefGoogle Scholar
  167. Sano M, Terada M, Ishii AI, Kino H, Anantaphruti M (1982) Studies on chemotherapy of parasitic helminths (V). Effects of niclosamide on the motility of various parasitic helminths. Experientia 38:547–559PubMedCrossRefGoogle Scholar
  168. Sasi PK, Raj RK (1975) Effect of piperazine on the level of phospholipid and on the activities of certain enzymes of phospholipid metabolism in human Ascaris lumbricoides. Experientia 31:1261–1262PubMedCrossRefGoogle Scholar
  169. Savin YI, Singin AS, Korolev GK (1977) Synthesis of 14C-piperazine and features of its distribution in animals. Khim Farm Zh 11:26–30Google Scholar
  170. Saz DK, Bonner TP, Karlin M, Saz HJ (1971) Biochemical observations on adult Nippo- strongylus brasiliensis. J Parasitol 57:1159–1162PubMedCrossRefGoogle Scholar
  171. Saz HJ (1972 a) Comparative biochemistry of carbohydrates in nematodes and cestodes. In: Bossche H vanden (ed) Comparative biochemistry of parasites. Academic, New York, pp 33–47Google Scholar
  172. Saz HJ (1972 b) Effects of anthelmintics on 32P-esterification in helminth metabolism. In: Bossche H vanden (ed) Comparative biochemistry of parasites. Academic, New York, pp 445–454Google Scholar
  173. Saz HJ, Lescure OL (1968) Effects of anticestodal agents on mitochondria from the nematode, Ascaris lumbricoides. Mol Pharmacol 4:407–410PubMedGoogle Scholar
  174. Schantz PM, Bossche H vanden, Eckert J (1982) Chemotherapy for larval echinococcosis in animals and humans: report of a workshop. Z Parasitenkd 67:5–26PubMedCrossRefGoogle Scholar
  175. Scheibel LW, Saz HJ, Bueding E (1968) The anaerobic incorporation of 32P into adenosine triphosphate byHymenolepis diminuta. J Biol Chem 243:2229–2235PubMedGoogle Scholar
  176. Selling HA, Vonk JW, Kaars-Sypestyn A (1970) Transformation of the systemic fungicide methyl thiophanate into 2-benzimidazole carbonic acid methyl ester. Chem Ind: 1625- 1626Google Scholar
  177. Seubert J, Pohlke R, Loebich F (1977) Synthesis and properties of praziquantel, a novel broad spectrum anthelmintic with excellent activity against schistosomes and cestodes. Experientia 33:1036–1037PubMedCrossRefGoogle Scholar
  178. Smith TC, Kinkel AW, Gryczko CM, Goulet JR (1976) Absorption of pyrvinium pamoate. Clin Pharmacol Ther 19:802–806PubMedGoogle Scholar
  179. Spaldonovä R (1981) Efficacy of febantel onTrichinella spiralis larvae in white mice. In: Kim CW Ruitenberg EJ, Teppema JS (eds) Trichinellosis. Proceedings of the 5th international conference on trichinellosis. Reedbooks, Surrey, pp 323–325Google Scholar
  180. Steiner K, Garbe A, Diekman HW, Nowak H (1976) The fate of praziquantel in the organism. I. Pharmacokinetics in animals. Eur J Drug Metab Pharmacokinet 2:85–95CrossRefGoogle Scholar
  181. Striebel HP (1976) 4-Isothiocyanato-4’-nitrodiphenylamine (C 9333 - GO/CGP 4540), an anthelmintic with an unusual spectrum of activity against intestinal nematodes, filariae and schistosomes. Experientia 32:457–458PubMedCrossRefGoogle Scholar
  182. Strufe R, Gönnert R (1960) Experimentelle Untersuchungen mit Af-(2’-chlor-4’-nitrophe- nyl)-5-chlorsalicylamid, einem neuen Bandwurmmittel. Arzneimittelforsch 10:886–890Google Scholar
  183. Strufe R, Gönnert R (1967) Über die Beeinflussung der Bandwurmstoffwechsel durch Arzneimittel. Z Tropenmed Parasitol 18:193–202PubMedGoogle Scholar
  184. Symoens J, Cree J de, Bever WFM van, Janssen PAJ (1979) Levamisole In: Goldberg ME (ed) Pharmacological and biochemical properties of drug substances, vol 2. American Pharmaceutical Association Academy of Pharmaceutical Sciences, Washington DC, pp 407–464Google Scholar
  185. Terada M, Ishii AI, Kino H, Sano M (1982 a) Studies on chemotherapy of parasitic helminths (VII). Effects of various cholinergic agents on the motility ofAngiostrongylus cantonensis. Jpn J Pharmacol 32:633–642PubMedCrossRefGoogle Scholar
  186. Terada M, Ishii AI, Kino H, Sano M (1982 b) Studies on chemotherapy of parasitic helminths (VIII). Effects of some possible neurotransmitters on the motility of Angiostrongylus cantonensis. Jpn J Pharmacol 32:643–653PubMedCrossRefGoogle Scholar
  187. Terada M, Ishii AI, Kino H, Sano M (1982 c) Studies on chemotherapy of parasitic helminths VI. Effects of various neuropharmacological agents on the motility of Dipy- lidium caninum. Jpn J Pharmacol 32:479–488PubMedCrossRefGoogle Scholar
  188. Terada M, Ishii AI, Kino H, Fujiu Y, Sano M (1982 d) Studies on chemotherapy of parasitic helminths (IX). Effects of praziquantel on the motility of various parasitic helminths and isolated host tissues. Experientia 38:549–553PubMedCrossRefGoogle Scholar
  189. The Merck Index, 9th edn (1976) Rahwag ND (ed) Merck, DarmstadtGoogle Scholar
  190. The Merck Index (1983) An encyclopedia of chemicals, drugs and biologicals. 10th edition. Merck & Co Inc. RahwaysGoogle Scholar
  191. Theodorides VJ, Chang J, Dicuollo CJ, Grass GM, Parish RC, Scott GC (1973) Oxi- bendazole, a new broad spectrum anthelmintic effective against gastrointestinal nematodes of domestic animals. Br Vet J 129:97–98Google Scholar
  192. Theodorides VJ, Parish RC, Fuchsman CH, Lee RM (1974) Bromoxanide, a new anthelmintic. Vet Ree (July 27th):84–85Google Scholar
  193. Theodorides VJ, Gyurik RJ, Kingsbury WC, Parish RC (1976) Anthelmintic activity of albendazole against liver flukes, tapeworms, lung- and gastrointestinal roundworms. Experientia 32:702–703PubMedCrossRefGoogle Scholar
  194. Thienpont D, Vanparijs O, Niemegeers C, Marsboom R (1978) Biological and pharmacological properties of flubendazole. Arzneimittelforsch 28:605–612PubMedGoogle Scholar
  195. Thomas H (1979) The efficacy of amidantel, a new anthelmintic, on hookworms and ascarids in dogs. Tropenmed Parasitol 30:404–408PubMedGoogle Scholar
  196. Tocco DJ, Buhs RP, Brown MD, Matzuk AR, Mertel HE, Harman RE, Trenner NR (1964) The metabolic fate of thiabendazole in sheep. J Med Chem 7:399–405PubMedCrossRefGoogle Scholar
  197. Tocco DJ, Egerton JR, Bowers W, Christensen VW, Rosenblum C (1965) Absorption, metabolism and elimination of thiabendazole in farm animals and a method for its estimation in biological materials. J Pharmacol Exp Ther 149:263–270PubMedGoogle Scholar
  198. Tollenaere JP, Moereels H, Bossche H vanden (1976) Comparison of the structure-activity relationships of substituted phenols as uncouplers of oxidative phosphorylation in rat liver and Ascaris muscle mitochondria. In: Bossche H vanden (ed) Biochemistry of parasites and host-parasite relationships. Elsevier, Amsterdam, pp 629–636Google Scholar
  199. Tollenaere JP, Moereels H, Raymaekers LA (1979) Atlas of the three-dimensional structure of drugs. Elsevier, AmsterdamGoogle Scholar
  200. Ueno H, Watanabe S, Fujita A (1959) Studies on anthelmintics of common liver fluke. J Jpn Vet Med Assoc 12:301Google Scholar
  201. Ueno H, Watanabe S, Fujita A (I960) Studies on anthelmintics against the common liver- fluke II. Action of bithionol in cattle. J Jpn Vet Med Assoc 13:151–155Google Scholar
  202. Vakil BJ, Dalai NJ, Shah PN, Koti ST, Mankodi NA, Sen HG, Vaidya AB (1977) Clinical evaluation of a new anthelmintic - C 9330 GO/CGP 4540 in human hookworm infection. Trans R Trop Med Hyg 71:247–250CrossRefGoogle Scholar
  203. Van Belle H (1972) Kinetics and inhibition of alkaline phosphatases from canine tissues. Biochim Biophys Acta 289:158–168PubMedGoogle Scholar
  204. Van Belle H (1976) Kinetics and inhibition of rat and avian alkaline phosphatases. Gen Pharmacol 7:53–58PubMedCrossRefGoogle Scholar
  205. Van Belle H, Janssen PAJ (1979) a-Ketoaldehydes, specific catalysts for thiol formation from levamisole. Biochem Pharmacol 28:1313–1318Google Scholar
  206. Vanden Bossche H (1972a) Biochemical effects of the anthelmintic drug, mebendazole. In: Bossche H vanden (ed) Comparative biochemistry of parasites. Academic, New York, pp 139–157Google Scholar
  207. Vanden Bossche H (1972) Studies on the phosphorylation in Ascaris mitochondria. In: Bossche H vanden (ed) Comparative biochemistry of parasites. Academic, New York, pp 455–468Google Scholar
  208. Vanden Bossche H (1976a) The molecular basis of anthelmintic action. In: Bossche H vanden (ed) Elsevier, Amsterdam, pp 533–572Google Scholar
  209. Vanden Bossche H (1976b) Effects of levamisole and tetramisole on the acetylcholinesterase activity. Janssen Research Products Information Service. Serial number: R 8299/4, R 12 564/3, BeerseGoogle Scholar
  210. Vanden Bossche H (1978) Chemotherapy of parasitic infections. Nature 273:626–630PubMedCrossRefGoogle Scholar
  211. Vanden Bossche H (1980 a) Chemotherapy of hymenolepiasis. In: Arai HP (ed) Biology of the tapeworm Hymenolepis diminuta. Academic, New York, pp 639–693Google Scholar
  212. Vanden Bossche H (1980 b) Peculiar targets in anthelmintic chemotherapy. Biochem Pharmacol 29:1981–1990PubMedCrossRefGoogle Scholar
  213. Vanden Bossche H, Nollin S de (1973) Effects of mebendazole on the absorption of low molecular weight nutrients by Ascaris suum. Int J Parasitol 3:401–407PubMedCrossRefGoogle Scholar
  214. Vanden Bossche H, Janssen PAJ (1983) Mode of action of known and experimental anti- filarial compounds. In: Anand N, Sen AB (eds) Proceedings symposium on “chemotherapy & immunology in the control of malaria, filaria and leishmaniasis”, February 17–21,1981, Lucknow, India. Tata McGraw-Hill, New Dehli, pp 187–201Google Scholar
  215. Vanden Bossche H, Verhoeven H (1982) Biochemical effects of the antiparasitic drug closantel. Proceedings of the British Society for Parasitology. Joint spring meeting 1981. Parasitology 84: (Li) (abstract)Google Scholar
  216. Vanden Bossche H, Claes J, Verhoeven H (1975) The uptake and distribution of mebendazole in Ascaris suum. In: Biol Res Report R 17 635, LVD, 2183, Section 11. Jans- sen Pharmaceutica, BeerseGoogle Scholar
  217. Vanden Bossche H. Verhoeven H, Vanparijs O, Lauwers H, Thienpont D (1979) Closantel, a new antiparasitic hydrogen ionophore. Arch Int Physiol Biochim 87:851–852Google Scholar
  218. Vanden Bossche H, Verhoeven H, Lauwers H (1980) Uncoupling of liver mitochondria associated with fasciolasis in rats - normalization by closantel. In: Bossche H vanden (ed) The host invader interplay. Elsevier, Amsterdam, pp 699–704Google Scholar
  219. Vanden Bossche H, Senft AW, Steck EA (1981) Antiparasitic agents: mode of action, drug resistance. In: Slusarski W (ed) Review of advances in parasitology. Proceedings of ICOPAIV. Polish Scientific Warszawa, pp 461–480Google Scholar
  220. Vanden Bossche H, Rochette F, Hörig C (1982) Mebendazole and related anthelmintics. In: Garattini S, Goldin A, Hawking F, Kopin IJ (eds) Advances in pharmacology and chemotherapy, vol 19. Academic Press, New York, pp 67–128Google Scholar
  221. Vanhoutte PM, Nueten JM van, Verbeuzen TJ, Laduron PM (1977) Differential effects of the isomers of tetramisole on adrenergic neurotransmission in cutaneous veins of dogs. J Pharmacol Exp Ther 200:127–140PubMedGoogle Scholar
  222. Van Nueten JM (1972) Pharmacological aspects of tetramisole. In: Bossche H vanden (ed) Comparative biochemistry of parasites. Academic, New York, pp 101–115Google Scholar
  223. Verheyen A, Borgers M, Vanparijs O, Thienpont D (1976) The effects of mebendazole on the ultrastructure of cestodes. In: Bossche H vanden (ed) Biochemistry of parasite? and host-parasite relationships. Elsevier, Amsterdam, pp 605–618Google Scholar
  224. Verheyen A, Borgers M, Bossche H vanden, Vanparijs O, Lauwers H, Thienpont D (1979) The localization of mitochondrial ATPase in the different tissues of the mature liver fluke Fasciola hepatica L. The influence of in vivo administration of closantel, a new antiparasitic hydrogen-ionophore. Biol Cell 35:36 aGoogle Scholar
  225. Verheyen A, Vanparijs O, Lauwers H, Thienpont D (1980) The influence of closantel administration to sheep on the ultrastructure of the adult liver fluke, Fasciola hepatica L. In: Bossche H vanden (ed) The host invader interplay. Elsevier, Amsterdam, pp 705–708Google Scholar
  226. Verhoeven HLE, Willemsens G, Bossche H vanden (1976) Uptake and distribution of leva- misole in Ascaris suum. In: Bossche H vanden (ed) Biochemistry of parasites and host- parasite relationships. Elsevier, Amsterdam, pp 573–579Google Scholar
  227. WHO (1974) Technical report serial number 542, GenevaGoogle Scholar
  228. Williamson RL, Metcalf RL (1967) Salicylanilides: a new group of active uncouplers of oxidative phosphorylation. Science 158:1694–1695PubMedCrossRefGoogle Scholar
  229. Wilson CG, Parke DV, Cawthorne MA (1973) Investigations of the 5-hydroxylation of thiabendazole in rat liver microsomal preparations. Biochem Soc Trans 1:195–196Google Scholar
  230. Wollweber H, Rolling H, Widdig A, Thomas H, Schulz H-P, Murmann P (1978) Febantel, a new broad-spectrum anthelminthic. Arzneimittelforsch 28:2193–2195PubMedGoogle Scholar
  231. Wollweber H, Niemers E, Flucke W, Andrews P, Schulz H-P, Thomas H (1979) Amidantel, a potent anthelmintic from a new chemical class. Arzneimittelforsch 29:31–32PubMedGoogle Scholar
  232. Yorke RE, Turton J A (1974) The influence of a range of anthelmintic drugs on the respiration of isolatedHymenolepis diminuta mitochondria. Z Parasitenkd 45:1–10PubMedCrossRefGoogle Scholar
  233. Zintz K, Frank W (1982) Ultrastructural modifications in Heterakis spumosa after treatment with febantel or mebendazole. Vet Parasitol 10:47–56PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1985

Authors and Affiliations

  • H. Vanden Bossche

There are no affiliations available

Personalised recommendations